Apogee Therapeutics to Participate in Upcoming March Investor Conferences

About this update from Apogee Therapeutics, Inc.

SAN FRANCISCO and BOSTON , Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. , (Nasdaq: APGE) today announced that members of management will participate at the following investor conferences. TD Cowen 45 th Annual Health Care Conference Date: Tuesday, March 4, 2025 Time: 2:30 p.m. ET Leerink Global Healthcare Conference Date: Tuesday, March 11, 2025Time: 8:40 a.m. ET A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology markets, including for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com . Investor Contact : Noel Kurdi VP, Investor Relations Apogee Therapeutics, Inc. [email protected] Media Contact: Dan Budwick 1AB [email protected] Source: Apogee Therapeutics

View stock analysis, news, and events for Apogee Therapeutics, Inc.